Health City Cayman Islands Ltd

Special purpose financial statements and audit report For the year ended on 31 March 2016

R J M J & Associates

Chartered Accountants

No. 14, 1st Floor, 80 Feet Road, Koramangala 1st Block, Bangalore 560 034 India. Telephone: +91 80 4132 0909

Independent Auditor's Report

To the Directors of Health City Cayman Islands Ltd

We have audited the accompanying financial statements of Health City Cayman Islands Ltd ('the Company') which comprise the balance sheet as at 31 March 2016, the statement of profit and loss and the cash flow statement for the year then ended, and a summary of significant accounting policies and other explanatory information which has been prepared by management in accordance with the basis of accounting described in note 1.1 to the financial statement.

Management's Responsibility for the Financial Statement

Management is responsible for the preparation of the financial statement in accordance with the basis of accounting described in note 1.1. This responsibility includes the design, implementation and maintenance of internal controls relevant to the preparation of the financial statement that gives a true and fair view and that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on the financial statement based on our audit.

We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statement. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by Company's management, as well as evaluating the overall presentation of the financial statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.



Independent Auditor's Report (continued)

Opinion

In our opinion and to the best of our information and accordingly to the explanations given to us, the financial statement give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2016 and its loss and its cash flows for the year ended on that date.

Basis of preparation and restriction on distribution and use

Without modifying our opinion, we draw attention to note 1.1 to the financial statement which describes the basis of preparation of these financial statement. These financial statement have been prepared to provide information to Narayana Hrudayalaya Limited (formerly known as Narayana Hrudayalaya Private Limited) for its financial reporting purposes. As a result, these financial statement may not be suitable for any other purpose. Our report is intended solely for Health City Cayman Islands Ltd and Narayana Hrudayalaya Limited and should not be distributed without our prior consent.

for R J M J & Associates

Chartered Accountants

Rabul Jain.

Firm's Registration Number: 015106S

Rahul Jain

Partner

Membership number: 065815

Bangalore

Date: 23 May 2016

Health City Cayman Islands Ltd Balance sheet as at 31 March 2016

Balance sheet as at 31 March 2010			(Amount in USD)
	Note	As at 31 March 2016	As at 31 March 2015
EQUITY AND LIABILITIES			
Shareholders' funds			
Share capital	2	750	466
Reserves and surplus	3 -	44,871,415 44,872,165	28,031,735 28,032,201
Share application money pending allotment	4	1,000,000	12,916,000
Non-current liabilities			
Long-term borrowings	5	25,111,000	27,615,000
	-	25,111,000	27,615,000
Current liabilities		2,594,410	3,507,807
Trade payables	6 7	4,402,307	2,726,563
Other current liabilities	-	6,996,717	6,234,370
TOTAL		77,979,882	74,797,571
ASSETS			
Non-current assets			
Fixed assets	8		
Tangible assets		62,679,107	66,204,237
Intangible assets		329,961	376,367
Long-term loans and advances	9	2,351,608	169,358
		65,360,676	66,749,962
Current assets			1.020.200
Inventories	10	2,118,989	1,838,396
Trade receivables	11	4,814,565	2,447,388
Cash and bank balances	12	3,696,013	2,406,269
Short-term loans and advances	9	470,629	395,456
Other current assets	13	1,519,010 12,619,206	960,100 8,047,60 9
TOTAL	3	77,979,882	74,797,571
TOTAL	0	17,272,002	14,121,371

Significant accounting policies

1

The notes referred to above form an integral part of the financial statements

As per our report of even date attached

for R J M J & Associates

Chartered Accountants

Firm Registration number: 015106S

Rabul Jain.

Rahul Jain

Partner

Membership number: 065815

Place: Bangalore Date: 23 May 2016 for Health City Cayman Islands Ltd

Dr. Ashutosh Raghuvanshi

Azhutosh

Director

Place: Bangalore Date: 23 May 2016 Dr. Devi Prasad Shetty

Director

Place: Bangalore Date: 23 May 2016

CM Land

Health City Cayman Islands Ltd

Statement of profit and loss for the year ended on 31 March 2016

(Amount in USD)

	Note	For the year ended 31 March 2016	For the year ended 31 March 2015
INCOME			7 041 176
Revenue from operations	14	15,301,437	7,841,175
Other income	15	28,484	971
Total revenue		15,329,921	7,842,146
EXPENSE			
Purchase of medical consumables, drugs and surgical equipments		2,778,292	2,400,199
Changes in inventories of medical consumables, drugs and surgical equipments	16	(273,363)	(839,501)
Employee benefits expense	17	11,466,402	9,059,676
	18	8,229,615	7,219,713
Other expenses Total expenses		22,200,946	17,840,087
Loss before interest, tax, depreciation and amortisation		(6,871,025)	(9,997,941)
Finance costs	19	1,751,198	1,580,004
Depreciation and amortisation	8	2,952,813	2,792,627
Loss before tax	-	(11,575,036)	(14,370,570)
Tax expense	1.15		
Loss for the year	95055	(11,575,036)	(14,370,570)
Loss per share (par value of USD 0.01 each)	22		7211
-Basic and diluted		(184)	(344)
A CONTRACTOR OF THE CONTRACTOR AND A CON			

The notes referred to above form an integral part of the financial statements.

As per our report of even date attached

for RJMJ & Associates

Significant accounting policies

Chartered Accountants

Firm Registration number: 015106S

Rabul Jain.

Rahul Jain

Partner .

Membership number: 065815

Place: Bangalore Date: 23 May 2016 for Health City Cayman Islands Ltd

Ashutoch

Dr. Ashutosh Raghuvanshi

Director

Place: Bangalore Date: 23 May 2016 Dr. Peyi Prasad Shetty

Director

Place: Bangalore Date: 23 May 2016

Health City Cayman Islands Ltd Cash flow statement for the year ended 31 March 2016

	For the year ended 31 March 2016	For the year ended 31 March 2015
Cash flow from operating activities		/11 270 570)
Loss before tax	(11,575,036)	(14,370,570)
Adjustments for:		
Depreciation and amortisation expense	2,952,813	2,792,627
Finance costs	1,751,198	1,580,004
Profit on sale of fixed asset, net	(49)	
Operating cash flow before working capital changes	(6,871,074)	(9,997,941)
Changes in trade receivables	(2,367,177)	(2,447,388)
Changes in inventories	(280,593)	(839,501)
Changes in loan and advances	(75,173)	(28,824)
Changes in other current assets	(558,910)	(960,100)
Changes in trade payables	(913,398)	775,470
Changes in liabilities and provisions	1,471,147	114,346
Cash used in operations	(9,595,178)	(13,383,937)
Income tax paid, net	-	
Net cash used in operating activities	(9,595,178)	(13,383,937)
Cash flow from investing activities	100 (chan was)	
Purchase of fixed assets	(1,480,029)	(5,932,890)
Sale of fixed assets	2,149	(7.022.000)
Net cash used in investing activities	(1,477,880)	(5,932,890)
Cash flow from financing activities	20 20 F 0000	
Proceeds from borrowings	(2,385,000)	(1.590.004)
Interest and other borrowings expeses	(1,751,198)	(1,580,004)
Proceeds from issue of shares (including share application money)	16,499,000	21,431,100
Net cash provided by financing activities	12,362,802	19,851,097
Not increase in cash and cash equivalents	1,289,744	534,270
Cash and cash equivalent at the beginning of the year	2,406,269	1,871,999
Cash and cash equivalent at the end of the year (refer note 12)	3,696,013	2,406,269

As per our report of even date attached

for RJMJ & Associates

Chartered Accountants

Firm Registration number: 015106S

Rahul Jain.

Rahul Jain

Partner

Membership number: 065815

Place: Bangalore Date: 23 May 2016 for Health City Cayman Islands Ltd

shutosh

Dr. Ashutosh Raghuvanshi

Director

Place: Bangalore Date: 23 May 2016 Dr. Devi Prasad Shetty

(Amount in USD)

Place: Bangalore Date: 23 May 2016

Background

Health City Cayman Islands Ltd ('the Company') was incorporated on 7 May 2010 as a Company limited by shares under the laws of the Cayman Islands. The registered office of the Company is located at, 89 Nexus Way, Camana Bay, Grand Cayman, KY1 - 9007, Cayman Islands. The Company is a joint venture entity between Ascension Health Ventures, LLC and Narayana Cayman Holdings Ltd and is primarily engaged in the business of rendering medical and healthcare services in Cayman Islands.

1. Significant accounting policies

1.1 Basis of preparation of financial statements

These financial statements have been prepared and presented under the historical cost convention on the accrual basis of accounting and comply with the Accounting Standards and other pronouncements issued by the Institute of Chartered Accountants of India ("ICAI").

The accounting policies have been consistently applied by the Company. The financial statements are presented in United States Dollars ("USD").

These financial statement are prepared specifically to provide information to Narayana Hrudayalaya Limited (formerly Narayana Hrudayalaya Private Limited) for the purposes of Consolidated financial statements of Narayana Hrudayalaya Limited (formerly Narayana Hrudayalaya Private Limited) for the year ended 31 March 2016 and may not be suitable for another purposes.

1.2 Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles in India requires the management to make judgement estimates and assumptions that affect the application of accounting policies and reported amounts of assets, liabilities, income and expenses and the disclosure of contingent liabilities on the date of the financial statements. Actual results could differ from those estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Any revision to accounting estimates is recognised prospectively in the current and future years.

1.3 Current and non - current classification

All assets and liabilities are classified into current and non - current.

Assets

An asset is classified as current when it satisfies any of the following criteria:

- a) It is expected to be realised in, or is intended for sale or consumption in, the Company's normal operating cycle;
- b) It is held primarily for the purpose of being traded;
- c) It is expected to be realised within 12 months after the reporting date; or
- d) It is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting date.

Current assets include the current portion of non - current financial assets.

All other assets are classified as non - current.



1. Significant accounting policies (continued)

1.3 Current and non - current classification (continued)

Liabilities

A liability is classified as current when it satisfies any of the following criteria:

- a) It is expected to be settled in the Company's normal operating cycle;
- b) It is held primarily for the purpose of being traded;
- c) It is expected to be settled within 12 months after the reporting date; or
- d) The Company does not have an unconditional right to defer settlement of the liability for at least 12 months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

Current liabilities include the current portion of non - current financial liabilities.

All other liabilities are classified as non - current.

Operating cycle

Operating cycle is the time between the acquisition of assets for processing and their realizations in cash or cash equivalents.

1.4 Inventories

The inventories of medical consumables, drugs and surgical equipments are valued at lower of cost or net realisable value. In the absence of any further estimated costs of completion and estimated costs necessary to make the sale, the net realisable value is the selling price. Cost of these inventories comprises of all costs of purchase and other costs incurred in bringing the inventories to their present location after adjusting for value added tax wherever applicable, applying the first in first out method.

1.5 Fixed assets, depreciation and amortisation

Fixed assets are stated at the cost of acquisition or construction less accumulated depreciation.

The cost of fixed assets not ready for their intended use before such date, are disclosed as capital work in progress. Advances paid towards acquisition of fixed assets outstanding as of the balance sheet date are disclosed under long-term loans and advances.

(a) Tangible fixed assets

Tangible fixed assets are carried at cost of acquisition or construction less accumulated depreciation and/ or accumulated impairment, if any. The cost of an item of tangible fixed assets comprises its purchase price, including import duties and other non-refundable taxes or levies, freight and any directly attributable cost of bringing the asset to its working condition for its intended use; any trade discounts and rebates are deducted in arriving at the purchase price. Subsequent expenditures related to an item of tangible fixed asset are added to its book value only if they increase the future benefits from the existing asset beyond its previously assessed standard of performance.



1. Significant accounting policies (continued)

1.5 Fixed assets, depreciation and amortisation (continued)

(b) Intangible fixed assets

Intangible assets are recorded at consideration paid for acquisition of such assets and are carried at cost less accumulated amortisation and accumulated impairment loss, if any.

Intangible assets are assessed for impairment whenever there is an indication that the intangible asset may be impaired.

(c) Depreciation and amortisation

Leasehold improvements are being amortised over the term of the lease, or estimated useful life of the assets, whichever is lower. Consideration paid for acquiring leasehold land is amortized over the lease term.

Freehold land is not depreciated.

Depreciation on additions and disposals during the year is provided on proportionate basis.

Depreciation is provided on the straight line method over the estimated useful life of fixed assets. The Company estimates the useful life of the fixed assets as follows:

Block of assets	Useful life
Building	40 years
Electrical installation	15 years
Medical equipment	10 years
Non-Medical Equipment	10 years
Air conditioning plant and air conditioners	15 years
Furniture and fixtures	10 years
Computers	3 years
Computer software	· 5 years
Vehicles	5 years

The Company believes that the useful life as given above best represent the useful life of the assets.

1.6 Borrowing cost

Borrowing costs are interest and other costs incurred by the company in connection with the borrowing of funds. Borrowing costs directly attributable to acquisition or construction of those fixed assets which necessarily takes a substantial period of time to get ready for their intended use are capitalised. Other borrowing costs are accounted as an expense in the period in which they are incurred.



1. Significant accounting policies (continued)

1.7 Revenue recognition

Revenue from operations

Revenue from medical and healthcare services to patients is recognised as revenue when the related services are rendered unless significant future uncertainties exist. Revenue is also recognised in relation to the services rendered to the patients who are undergoing treatment/observation on the balance sheet date to the extent of services rendered.

Revenue is recognised net of discounts given to the patients.

Revenue from sale of medical consumables and drugs within the hospital premises is recognised when property in the goods or all significant risks and rewards of their ownership are transferred to the customer and no significant uncertainty exists regarding the amount of the consideration that will be derived from the sale of the goods and regarding its collection.

'Unbilled revenue' represents value of medical and healthcare services rendered in excess of amounts billed to the patients as at the balance sheet date. 'Unearned revenue' comprises billings in excess of earnings.

1.8 Earnings per share

The basic earnings per share is computed by dividing the net profit attributable to equity shareholders for the year by the weighted average number of equity shares outstanding during the year.

Diluted earnings per share is computed by dividing the net profit attributable to equity shareholders for the year relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share from continuing ordinary operations.

1.9 Provisions and contingencies

Provision is recognised if, as a result of obligating events, there is a present obligation that probably requires an outflow of resources and a reliable estimate can be made of the amount of obligation.

The disclosure of contingent liability is made if, as a result of obligating events, there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources.

No provision or disclosure is made if, as a result of obligating events, there is a possible obligation or a present obligation where the likelihood of an outflow of resources is remote.

Provisions for onerous contracts, i.e. contracts where the expected unavoidable costs of meeting the obligations under the contract exceed the economic benefits expected to be received under it, are recognised when it is probable that an outflow of resources embodying economic benefits will be required to settle a present obligation as a result of an obligating event based on a reliable estimate of such obligation.



1. Significant accounting policies (continued)

1.10 Impairment of assets

The Company assesses at each balance sheet date using external and internal sources, whether there is any indication that an asset or a group of assets comprising a cash-generating unit may be impaired. An impairment loss is recognized wherever the carrying value of an asset exceeds its recoverable amount. If any such indication exists, the Company estimates the recoverable amount of the asset. For an asset or group of assets that does not generate largely independent cash inflows, the recoverable amount is determined for the cash-generating unit to which the asset belongs. If such recoverable amount of the asset or the recoverable amount of the cash-generating unit to which the asset belongs is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is recognised in the statement of profit and loss. If at the balance sheet date there is an indication that if a previously assessed impairment loss no longer exists, the recoverable amount is reassessed and the asset is reflected at the recoverable amount subject to a maximum of depreciable historical cost. An impairment loss is reversed only to the extent that the carrying amount of asset does not exceed the net book value that would have been determined, if no impairment loss had been recognised.

1.11 Leases

Leases under which the Company assumes substantially all the risks and rewards of ownership are classified as finance leases. Such assets are capitalised at fair value of the asset or present value of the minimum lease payments at the inception of the lease, whichever is lower.

Lease payments under operating lease are recognised as an expense in the statement of profit and loss on a straight line basis over the lease term. Lease term is the non-cancellable period for which the Company has agreed to take on lease the asset together with any further periods for which the Company has the option to continue the lease and at the inception of the lease it is reasonably certain that the Company will exercise such an option.

1.12 Employee benefits

Post-employment benefits

Define contribution plans

A defined contribution plan is post-employment benefit plan under which an entity pays specified contributions to separate entity and has no obligation to pay any further amounts. The company makes specified obligations towards employee pension fund to Government administered pension fund plan which is a defined contribution plan. The Company's contribution is recognized as an expense in the statement of profit and loss during the period in which the employee renders the related service.

1.13 Cash and cash equivalents

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.



1. Significant accounting policies (continued)

1.14 Cash flow statement

Cash flows are reported using the indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated.

1.15 Income taxes

There are no taxes on income, profits or capital gains in the Cayman Islands. The Company has received an undertaking from the Governor in the Cabinet of the Cayman Islands exempting it from all such taxes for a period of 20 years should such taxes be enacted. Accordingly there are no taxes recorded in the financial statements.

1.16 Measurement of Earnings Before Interest, Tax, Depreciation and Amortisation

As permitted by the Guidance Note on the Revised Schedule VI, the Company has elected to present earnings before interest, tax, depreciation and amortization (EBITDA) as a separate line item on the face of the statement of profit and loss. In its measurement of EBITDA, the Company includes other income but does not include depreciation and amortization expense, finance costs and tax expense.



	31 March 2016

2	Share capital		
	a) Authorised capital 5,000,000 equity shares (31 March 2015: 5,000,000 equity shares) of USD 0.01 each	50,000	50,000
	b) Issued, subscribed and paid-up capital 53,550 (31 March 2015: 33,262) class X equity shares of USD 0.01 each, fully paid-up	536	333
	21,450 (31 March 2015: 13,323) class Y equity shares of USD 0.01 each, fully paid-up	215	133
	21,100 (31 March 2010) 10,000 / Clary march 2010 of the control of	750	466
		-	

(c) Reconciliation of the number of equity shares outstanding at the end of the period:

31 March 201	6	31 March 201	5
Number of shares	Amount	Number of shares	Amount
33,262	333	23,570	236
20,288	203	9,692	97
53,550	536	33,262	333
31 March 201	6	31 March 201	5
Number of shares	Amount	Number of shares	Amount
13,323	133	9,430	94
8,127	81	3,893	39
21.450	215	13 323	133
	Number of shares 33,262 20,288 53,550 31 March 201 Number of shares 13,323 8,127	33,262 333 20,288 203 53,550 536 31 March 2016 Number of shares Amount 13,323 133 8,127 81	Number of shares Amount Number of shares 33,262 333 23,570 20,288 203 9,692 53,550 536 33,262 Number of shares Amount Number of shares 13,323 133 9,430

(d) List of persons holding more than 5 percent shares in the Company:

	31 March 2016		31 March 2015	
	Number of shares	% holding	Number of shares	% holding
Ascension Health Ventures, LLC (Class X equity shares)	53,550	71.4%	33,262	71.4%
Narayana Cayman Holdings Ltd (Class Y equity shares)	21,450	28.6%	13,323	28.6%
, many man cary mana accordings and (common equity)	75,000	100%	46,585	100.00%

- (e) Rights, preference and restriction attached to equity shares including distribution of dividends:
- i) The Company has two class of equity shares referred to as class X equity shares and class Y equity shares, having a par value of USD 0.01 each. All the equity shares rank equally with regard to dividend and share in the Company's residual assets. Each holder of equity shares is entitled to one vote per share. Dividends will be payable as and when the Board propose and the share holders approves the same. The Company has not declared any dividend during the current year and previous year.
- ii) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by shareholders.
- (f) Number of shares held by holding company:
- 53,550 class X equity shares (31 March 2015: 33,262) of USD 0.01 each are held by Ascension Health Ventures, LLC, the Holding Company as at 31 March 2016.
- (g) The Company does not have any shares reserved for issue under any other contracts.
- (h) There has been no buy back of shares, issue of shares by way of bonus shares or issue of shares pursuant to contract without payment being received in eash during the current year and the previous years/periods since the date of incorporation i.e. 7 May 2010, except that the Company has issued 3,000 class Y equity shares to Narayana Cayman Holdings Ltd for considerations other than eash towards capital contribution as per Joint Venture Agreement dated 25 July 2012.

		(Amount in USD)
	As at 31 March 2016	As at 31 March 2015
3 Reserves and surplus		
Securities premium account	47 504 524	22,000,670
Opening balance	46,584,534	32,999,670
Add: Securities premium on issue of equity shares during the year	28,414,716	13,584,864
At the end of the year	74,999,250	46,584,534
Deficit (Debit balance in the statement of profit and loss):		
At the commencement of the year	(18,552,799)	(4,182,229)
Add: Net loss for the year	(11,575,036)	(14,370,570)
At the end of the year	(30,127,835)	(18,552,799)
Total Reserves and Surplus	44,871,415	28,031,735

	(Amount in USD)
As at 31 March 2016	As at 31 March 2015
1.000,000	12,916,000
1,000,000	12,916,000

(Amount in USD)

4 Share application money pending allotment

Details of share application money pending allotment

(a) As at 31 March 2016, the Company has received USD 714,000 and USD 286,000 (31 March 2015; USD 9,221,714 and USD 3,694,286) towards share application money for issue of class X and class Y equity shares respectively to Ascension Health Ventures, LLC and Narayana Cayman Holdings Ltd. Number of shares proposed to be issued for share application money pending allotment outstanding as at 31 March 2016 is 714 Class X and 286 Class Y equity shares (31 March 2015; 9,221 Class X and 3,694 Class Y equity shares). Application money outstanding as at 31 March 2016 and 31 March 2015 represents amount received at the rate of Rs USD 1,000 each towards par value of shares and security premium.

- (b) Securities premium on account of shares pending allotment amounts to USD 999.99 per share on 1000 equity shares and 12,915 shares as at 31 March 2016 and 31 March 2015 respectively.
- (c) The Company has sufficient authorized equity share capital to cover the share capital on allotment of shares pending allotment as at 31 March 2016 and 31 March 2015.
- (d) There are no interest accrued and due on amount due for refund as of 31 March 2016 and 31 March 2015.
- (e) No shares are pending for allotment beyond the period for allotment as of 31 March 2016 and 31 March 2015.

5 Long - term borrowings	Non current	portion	Current mat	(Amount in USD) urities
2 Long - term borrowings	As at 31 March 2016	As at 31 March 2015	As at 31 March 2016	As at 31 March 2015
Secured Term loans		27 (15 000	2 504 000	2,385,000
- from banks	25,111,000	27,615,000	2,504,000	2,385,000

Term loans from banks:

The Company has outstanding term loan taken from Bank of America amounting to USD 27,615,000 (31 March 2015: USD 30,000,000) against sanction limit of USD 30,000,000 repayable in 10 annual installments as per loan agreement from 30 June 2015 onwards till 30 June 2024. Interest is applicable at the rate of LIBOR phs 2.85% per annum. The loan is secured by bank guarantee from the Parent Companies of the joint venture partners in ratio of the joint venture partners shareholdings.

Trade payables Trade payables (refer note 23) 2,594,410 3,507,8			(Amount in USD)
Trade payables (refer note 25) 2,594,410 3,507,8			As at 31 March 2015
2,594,410 3,507,8		2,594,410	3,507,807
As at 31 March 2016 31 March 2 7 Other current liabilities Current maturities of long-term borrowings (refer note 5) Creditors for capital goods Advance received from customers and patients Statutory dues payable Accused expenses As at 31 March 2016 31 March 2 2,504,000 2,385,0 227,3 31,061,283 52,711 471,499 114.3	Trade payables (refer note 25)	2,594,410	3,507,807
7 Other current liabilities Current maturities of long-term borrowings (refer note 5) Creditors for capital goods Advance received from customers and patients Statutory dues payable Accrused expenses 31 March 2016 2,504,000 2,385,0 227,3 312,814 227,3 31 March 2016 31 March 2016 2,504,000 31,061,283 31,061,283 471,499 114,3			(Amount in USD)
Current maturities of long-term borrowings (refer note 5) 2,504,000 2,385,0 Creditors for capital goods 312,814 227,0 Advance received from customers and patients 1,061,283 Statutory dues payable 52,711 Accrused expenses 471,499 114.3			As at 31 March 2015
Accrued expenses 471,499 114.:	Current maturities of long-term horrowings (refer note 5) Creditors for capital goods Advance received from customers and patients	312,814 1,061,283	2,385,000 227,217 -
			114,346 2,726,563



Health City Cayman Islands Ltd Notes to the financial statements for the year ended 31 March 2016

1	π	
ì	ŏ	
į	ö	
1	65	
۹	n	
i	ಪ	
1	Ħ	
à	5	۱
۰	÷	
	,	

Particuars Tangible assets (Owned) Land and related infrastructure cost Building Medical equipment Electrical installations Electrical installations	Additions during the year					AVVEINGBLE OF AVAILABILITY		The state of the s	
assets related infrastructure cost 3 quipment installations		Deletions during the year	As on 31 March 2016	As on 01 April 2015	Charge for the	Deletions during the year	As on 31 March 2016	As on 31 March 2016	As on 01 April 2015
related infrastructure cost 3 quipment installations									
	•	1 957 139	11,268,323				1	11,268,323	13,225,462
81	147 976		34,496,990	852,242	862,794		1,715,036	32,781,954	33,496,772
8	192,588		8,419,568	709,797	790,828	•	1,500,625	6,918,943	6,823,010
Aller and an aller and an arrangement	27.475		4,086,065	268,858	271,431		540,289	3,545,776	3,779,632
	15169		5,441,872	361,226	363,378		724,604	4,717,268	5,065,477
netuding an economists	38 316		1,456,808	138.941	145,035		283,976	1,182,832	1,289,551
	80 045	1 728	2,462,485	233,541	242,650	(171)		1,986,471	2,140,717
ind Havedres	27.744	858	492.011	143,062	160,567	(306)	303,323	188,688	322,050
Computers	48 902		119.228	8,750	21,617		30,377	88,851	61,566
(89)	1,292,409	1,959,723	68,253,351	2,716,427	2,858,300	(483)	5,574,244	62,679,107	66,204,237
Intangible assets	48 107		\$00.674	76.200	94.513		170,713	329,961	376,367
Total (B) 452,567	48,107		500,674	76,200	94,513		170,713	329,961	376,367
136 242 007	1 240 216	1 040 773	68.754.025	2.792.627	2.932.813	(483)	5,744,957	890,600,69	66,580,604
Grand John (ATD)	40 272 321	and to contra	60 373 231		2.792.627			66,580,604	



				(Amount in USD)
9 Long-term and Short-term loans and advances	As at 31 March 2016	As at 31 March 2015	As at 31 March 2016 Short-ter	As at 31 March 2015
(Unsecured and considered good)	Long-ter	m		
Capital advances	394,469	169,358	-	
Security deposits Loans and advances / other receivables from related parties (refer note 23)	1,957,139		152,227 20,077	127,200 33,736
Advance to suppliers	29	-	246,395	198,293
Advance to employees	-	-	20,319	2 (227
Receivable from suppliers and customers for expenses	2,351,608	169,358	31,610 470,629	36,227 395,456
			As at	(Amount in USD) As at
			31 March 2016	31 March 2015
10 Inventories (Valued at lower of cost and net realisable value)				
Medical consumables, drugs and surgical equipments			1,949,142	1,749,084
Goods-in-transit			169,847 2,118,989	89,312 1,838,396
				(Amount in USD)
			As at 31 March 2016	As at 31 March 2015
11 Trade receivables Unsecured				
Receivables outstanding for a period exceeding six months				
from the date they become due for payment*			349,559	194,326
Considered good			446,089	10,228
Considered doubtful Less: Provision for doubtful receivables			(446,089)	(10,228
			349,559	194,326
Other receivables*			4,465,005	2,253,061
Considered good Considered doubtful			-	118,582
Less: Provision for doubtful receivables			4,465,005	2,253,061
			4,814,565	2,447,388
* refer note 23				
				(Amount in USD
			As at 31 March 2016	As a 31 March 201
12 Cash and bank balances				
Cash and cash equivalents Cash on hand			2,434	3,204
Balance with banks:			3,693,579	2,403,065
- in current accounts			3,696,013	2,406,265
				(Amount in USI
			As at 31 March 2016	As a 31 March 201
13 Other current assets			1,146,651	933,818
Prepaid expenses Unbilled revenue			372,358	26,283
Calle Hardy and Called			1,519,009	960,100



		(Amount in USD)
	For the year ended 31 March 2016	For the year ended 31 March 2015
14 Revenue from operations		
Income from medical and healthcare services	15,110,361	7,792,020
Sale of medical consumables and drugs	191,076 15,301,437	49,155 7,841,175
		(Amount in USD)
	For the year ended 31 March 2016	For the year ended 31 March 2015
15 Other income		
Gain on sale of fixed assets, net	49	-
Foreign exchange gains, net	2,514 25,556	-
Processing fee income Miscellaneous income	366	971
Miscellaneous meonic	28,484	971
		(Amount in USD)
	For the year ended 31 March 2016	For the year ended 31 March 2015
16 Changes in inventories of medical consumables, drugs and surgical equipments		
Inventory at the beginning of the year	1,838,396	998,895
Inventory at the end of the year	2,111,759	1,838,396
	(273,363)	(839,501)
		(Amount in USD)
	For the year ended 31 March 2016	For the year ended 31 March 2015
17 Employee benefit expenses		
Salaries and wages	7,787,902	6,165,630
Contribution to social security and other funds	269,679	207,191
Staff welfare expenses	3,408,821	2,686,856
	11,466,402	9,059,676



.100	es to the financial statements for the year ended 31 March 2010		(Amount in USD)
		For the year ended 31 March 2016	For the year ended 31 March 2015
18	Other expenses		
	Hospital operating expenses		74.100
	Hospital general expenses	139,272	74,190
	Variable cost of utilities	1,631,018	1,690,531
	Patient food and welfare expenses	186,219	66,910
	Repairs and maintanence	20.22	277 400
	- Hospital equipment	789,762	376,499
	- Building	330,886	221,191
	- others	340,070	345,349
	Software licence fee	120,000	120,000
	Land scaping expenses	32,989	32,798
	House keeping expenses	58,618	88,738
	Medical gas charges	7,575	175,628
		3,636,409	3,191,834
	Administrative expenses		004 000
	Advertisement and publicity	1,801,080	886,802
	Bank charges	54,261	32,132
	Printing and stationery	66,925	101,123
	Security charges	2,236	4,398
	Legal and professional fees	1,026,899	1,334,010
	Travelling and conveyance	13,004	45,958
	Cafetaria expenses	36,498	136,340
	Insurance	931,247	954,861
	Cable charges	15,887	18,943
	Telephone and communication	167,850	142,695
	Books and periodicals	4,667	8,697
	Rates and taxes	105,640	181,789
	Recruitment expenses	220	17,906
	Provision for doubtful receivables	317,279	128,810
	Bad debt written-off	44,302	1.5
	Miscellaneous expenses	5,210 4,593,206	33,415 4,027,879
		0.220.615	7.210.712
		8,229,615	7,219,713
			(Amount in USD)
		For the year ended	For the year ended
		31 March 2016	31 March 2015
19	Finance cost		
	Interest		
	- on term loans from banks	888,182	666,419
	- on others	390	1,085
	Guarantee fee	862,626	912,500
	NAME OF THE PARTY	1,751,198	1,580,004
		The second secon	THE RESERVE TO SHARE THE PARTY OF THE PARTY



20 Contingent liabilities and commitments

Estimated amount of contracts remaining to be executed on capital account (net of advances) as at 31 March 2016 amount to USD 213,040 (31 March 2015; USD 72,326).

21 Auditors' remuneration (provisional basis)

	For the year ended 31 March 2016	
As statutory auditors	25,000	107,785
Total	25,000	107,785

22 Earnings per share

The following table sets forth the computation of basic and diluted earnings per share:

Particulars	For the year ended 31 March 2016	
Loss after tax for the year, attributable to equity shareholders Weighted average number of equity shares of USD 0.01 each used for calculation of earnings per share	(11,575,036) 62,935	
Loss per share	(184)	(344)

The Company has not issued any potential dilutive equity shares.

23 Related party transactions

(a) Details of related parties

Nature of relationship Ultimate Holding Company Holding Company Fellow Subsidiary Enterprise under significant influence of Director / Key Managerial person ('KMP')

Enterprise having significant influence

Name of related parties
Ascension Health Alliance
Ascension Health Ventures, LLC
TriMcdx Cayman Ltd.
Consulting Services Ltd
Have A Heart Foundation
Health City Development Ltd
Office Supply Ltd

Wyndham Reef Resort Grand Cayman Narayana Cayman Holdings Ltd Narayana Hrudayalaya Limited (formerly

Narayana Hrudayalaya Limited (formerly Narayana Hrudayalaya Private Limited)



23 Related party transactions (continued)

	Holding Company	Fellow	Enterprise under significant	Enterprise having	
Transaction	/Ultimate Holding	Subsidiary	influence of Director / KMP	significant influence	Total
Allotment of equity shares (including security premium):					
Ascension Health Ventures, LLC	20,288,000	-	-	-	20,288,000
Narayana Cayman Holdings Ltd		-	-	8,127,000	8,127,000
Total	20,288,000	17	-	8,127,000	28,415,000
Share application money received:					
Ascension Health Ventures, LLC	11,780,286	-	-	-	11,780,286
Narayana Cayman Holdings Ltd	-	-	-	4,718,714	4,718,714
Total	11,780,286	-	-	4,718,714	16,499,000
Purchase of pharma products and medical accessories: Narayana Hrudayalaya Limited (formerly Narayana			-	723,277	723,277
Hrudayalaya Private Limited)					
Purchase of fixed assets:					
TriMedx Cayman Ltd.	-		1723		
Narayana Hrudayalaya Limited (formerly Narayana Hrudayalaya Private Limited)				256,563	256,563
Consulting Services Ltd	-		158,987	-	158,987
Office Supply Ltd	-	-	27,959	-	27,959
Total	-		186,946	256,563	443,509
Gurantee commission:					
Ascension Health Alliance	616,568	-	-	-	616,568
Narayana Hrudayalaya Limited (formerly Narayana Hrudayalaya Private Limited)	-	-	-	246,058	246,058
Total	616,568	-	72	246,058	862,626
Other expenses:					
TriMedx Cayman Ltd.		744,247			744,247
Consulting Services Ltd	2	,	1,012,422	133,000	1,145,422
Office Supply Ltd		2	51,241	-	51,241
Narayana Hrudayalaya Limited (formerly Narayana Hrudayalaya Private Limited)	*	-	-		-
Wyndham Reef Resort Grand Cayman	-		269,372	_	269,372
Total	-	744,247	1,333,035	133,000	2,210,282
Income from medical and healthcare services:					
Consulting Services Ltd	-	-	23,775		23,775
Have A Heart Foundation	-	-	542,525		542,525
Total		-	566,300		566,300
Other income					
TriMedx Cayman Ltd.	75	25,556	-	*	25,556
Advance to supplier					
Consulting Services Ltd		-	44,357	-	44,357
Narayana Hrudayalaya Limited (formerly Narayana Hrudayalaya Private Limited)	5×	-	-	56,070	56,070
Trimedix	70	544	0-0		544
Health City Development Ltd Total	-	-	1,957,139		1,957,139
0.086	70	544	2,001,496	56,070	2,058,110
Payment of expenses on behalf of the Company: Narayana Hrudayalaya Limited (formerly Narayana	-	_		94,358	04.359
Hrudayalaya Private Limited)				24,330	94,358
Consulting Services Ltd		-	18,000	-	18,000
Payment of expenses by the Company on behalf of:	*	-	18,000	94,358	112,358
Ascension Health Alliance	(3.43)	-	94	2	
Consulting Services Ltd	_	-	7,300	_	7,300
TriMedx Cayman Ltd.	3.5	329,484	-		329,484
Have A Heart Foundation		-	96,156	-	96,156
Narayana Hrudayalaya Limited (formerly Narayana			C20700086	13,354	13,354
Hrudayalaya Private Limited)					
Hrudayalaya Private Limited) Narayana Cayman Holdings Ltd Total		-		137,074	137,074



23 Related party transactions (continued)

Transaction	Holding Company /Ultimate Holding	Fellow Subsidiary	Enterprise under significant influence of Director / KMP	Enterprise having significant influence	Total
Allotment of equity shares (including security	7Citimate Holding	Substituary	mindence of Director / KNII	significant influence	Tota
oremium):					
Ascension Health Ventures, LLC	9,692,000		8723		9,692,000
Narayana Cayman Holdings Ltd	2,022,000	-		2 902 000	
Total	9,692,000			3,893,000 3,893,000	3,893,000 13,585,000
Share application money received:					
Ascension Health Ventures, LLC	9,221,714		823		9,221,714
Narayana Cayman Holdings Ltd	_	-		3,694,286	3,694,286
Total	9,221,714			3,694,286	12,916,000
Ourchase of pharma products and medical accessories:					
Narayana Hrudayalaya Limited (formerly Narayana		2		781,383	781,383
Hrudayalaya Private Limited)				104,000	701,505
urchase of fixed assets:					
TriMedx Cayman Ltd.	23	55,605	-		55,605
Consulting Services Ltd		-	77,564	_	77,564
Narayana Hrudayalaya Limited (formerly Narayana		_	-	108,077	108,077
Hrudayalaya Private Limited)				100,017	100,011
Total		55,605	77,564	108,077	241,246
Gurantee commission:					
Ascension Health Alliance	700,860		_		700,860
Narayana Hrudayalaya Limited (formerly Narayana Hrudayalaya Private Limited)	-	-	-	211,640	211,640
Total	700,860			211,640	912,500
Other expenses:					
Ascension Health Alliance	10,101				10.101
TriMedx Cayman Ltd.		376,499		-	10,101
Consulting Services Ltd		370,433	932,122	-	376,499
Narayana Hrudayalaya Limited (formerly Narayana	_	_		170.000	932,122
Hrudayalaya Private Limited)		0000000000		120,000	120,000
Total	10,101	376,499	932,122	120,000	1,438,722
ncome from medical and healthcare services:					
Consulting Services Ltd	-	-	10,028	2	10,028
hyment of expenses on behalf of the Company:					
Narayana Hrudayalaya Limited (formerly Narayana				10.240	40.240
Hrudayalaya Private Limited)			-	49,340	49,340
ayment of expenses by the Company on behalf of:					
Ascension Health Alliance	28,929	_			20.020
Consulting Services Ltd	-			-	28,929
TriMedx Cayman Ltd.	_	96,908	9,530	- 24	9,530
Narayana Cayman Holdings Ltd		20,200	-	100.14	96,908
Total	28,929	96,908	0.520	120,161	120,161
	40,747	20,208	9,530	120,161	255,528
		016			

(d) The balances receivable from and payable to related Transaction	Holding Company	Fellow	Enterprise under significant	Enterprise having	(Amount in USD)
Trade payables:	/Ultimate Holding	Subsidiary	influence of Director / KMP	significant influence	Total
Ascension Health Alliance	202 447				
Consulting Services Ltd	302,667	-	-		302,667
Narayana Hrudayalaya Limited (formerly Narayana		157	80,482		80,482
Hrudayalaya Private Limited)		-	-	815,352	815,352
TriMedx Cayman Ltd.					200,000
Office Supply Ltd	175	97,317	-		97,317
Wyndham Reef Resort Grand Cayman	-	-		-	
Total	0.00		9,612	_	9,612
a venag	302,667	97,317	90,094	815,352	1,305,430
Irade receivables:					
Consulting Services Ltd			*		
Have A Heart Foundation	-	-	911	-	911
Total	-	-	7,450	-	7,450
1004		2.5	8,361	7.	8,361
loans and advances / other receivables:					
Narayana Cayman Holdings Ltd					
TriMedx Cayman Ltd.			-	18,328	18,328
Consulting Services Ltd	-	3,405	-		3,405
Have A Heart Foundation		-	44,357		44,357
	-	-	1,749		1,749
Health Ciy Development Ltd Total		-	1,957,139	_	1,957,139
- Viai		3,405	2,003,245	18,328	2,024,978



23 Related party transactions (continued)

(e) The balances receivable from and payable to related parties as at 31 March 2015

(Amount in USD)

Transaction	Holding Company /Ultimate Holding	Fellow Subsidiary	Enterprise under significant influence of Director / KMP	Enterprise having significant influence	Total
Trade payables:	- P		minute of Director / It.mi	againcant innuence	rotat
Ascension Health Alliance	490,351				400.261
Consulting Services Ltd	-		79,853		490,351
Narayana Hrudayalaya Limited (formerly Narayana	-	-	17,633	764.212	79,853
Hrudayalaya Private Limited)			-	764,213	764,213
TriMedx Cayman Ltd.		279,591			270 501
Total	490,351	279,591	79,853	764,213	279,591 1,614,008
Trade receivables:					
Consulting Services Ltd			647	_	647
Loans and advances / other receivables;					87.57/
Narayana Cayman Holdings Ltd		-		26 400	24.400
Narayana Hrudayalaya Limited (formerly Narayana		0.5	-	26,400	26,400
Hrudayalaya Private Limited)					
TriMedx Cayman Ltd.	-	2.061	-	4,475	4,475
Total	-	2,861		-	2,861
17-LB1	-	2,861	-	30,875	33,736

24 Employee benefits:

Defined contribution plan

The amount recognized as an expense towards contribution to social secuirty funds for the period aggregated to USD 269,679 (31 March 2015; USD 207,191)

25 These financial statement are prepared by the Company specifically to provide information to Narayana Hrudayalaya Limited (formerly Narayana Hrudayalaya Private Limited) for the purposes of Consolidated financial statements of Narayana Hrudayalaya Limited (formerly Narayana Hrudayalaya Private Limited) for the year ended on 31 March 2016 and may not be suitable for other purposes.

As per our report of even date attached

for R J M J & Associates Chartered Accountants

Firm Registration number: 015106S

Kahul Jain

Rabul Jain Partner

Membership number: 065815

Place: Bangalore Date: 23 May 2016 for Health City Cayman Islands Ltd

Dr. Ashutosh Raghuvanshi Director

Place: Bangalore Date: 23 May 2016

ad Shetty

Place: Dangalore Date 23 May 2016